Jonathan S. Stamler, MD, Director, Harrington Discovery Institute, is an internationally renowned physician-scientist, recognized for the discovery of protein S-nitrosylation, a ubiquitous mechanism for controlling protein function that operates across phylogeny and in all cell types and tissues, and that is commonly dysregulated in disease. His work on S-nitrosylation is notable for providing new insights into mammalian physiology, including the regulation of cardiac contractility and the discovery of red blood cell-mediated vasodilation, which is essential for oxygen delivery to all tissues. Dr. Stamler’s laboratory is also known for groundbreaking work on hemoglobins in mammals, microbes and worms, in the process discovering the vasoregulatory role of a third gas (nitric oxide) in the mammalian respiratory cycle (thereby redefined as a 3-gas system: NO/O2/CO2) as well as new enzymatic functions of hemoglobins that protect against nitric oxide in lower organisms. Dr. Stamler also identified the molecular mechanism of nitroglycerin bioactivation and tolerance.
Dr. Stamler is a graduate of Brandeis University in Boston, and received his medical degree from Mount Sinai School of Medicine in New York. He completed his internship, residency and fellowships in cardiovascular and pulmonary medicine at Harvard Medical School and Brigham and Women’s Hospital, Boston. He was on the faculty at Harvard University before spending 16 years at Duke University and the Howard Hughes Medical Institute, Durham, NC.
Dr. Stamler relocated to Case Western Reserve University School of Medicine and University Hospitals Case Medical Center in 2010, where he holds the Reitman Family Distinguished Chair of Cardiovascular Innovation, is a professor of medicine and biochemistry and director of the Institute for Transformative Molecular Medicine as well as director of the Harrington Discovery Institute.
Dr. Stamler has published more than 275 original articles and edited two books. He has co-founded seven biotechnology companies and licensed two additional programs to major pharmaceutical companies. He holds more than 125 patents and patent applications, and has been recognized by several awards and prizes.